Discovery of 5,7-Dimethoxy-2-(3,4,5-trimethoxyphenoxy)-chromen-4-one with Lipid Lowering Effects in Hepatocytes
The population with nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH) is increasing. However, no medicine is indicated for treating these diseases clinically nowadays. Therefore, there is an urgent need to develop a new drug to overcome NAFLD and NASH. Capillarisin, a...
Main Authors: | Yi-Han Chang, Chia-Hung Yen, Chih-Chung Lai, Hsuan-Yu Lai, Hsin-Yi Hung |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2022-04-01
|
Series: | Pharmaceuticals |
Subjects: | |
Online Access: | https://www.mdpi.com/1424-8247/15/4/449 |
Similar Items
-
Saroglitazar suppresses the hepatocellular carcinoma induced by intraperitoneal injection of diethylnitrosamine in C57BL/6 mice fed on choline deficient, l-amino acid- defined, high-fat diet
by: Suresh R. Giri, et al.
Published: (2023-01-01) -
Modulation of Cyclins, p53 and Mitogen-Activated Protein Kinases Signaling in Breast Cancer Cell Lines by 4-(3,4,5-Trimethoxyphenoxy)benzoic Acid
by: Kuan-Han Lee, et al.
Published: (2014-01-01) -
Cellular senescence in hepatocytes contributes to metabolic disturbances in NASH
by: Laurianne Bonnet, et al.
Published: (2022-08-01) -
Circulating indian hedgehog is a marker of the hepatocyte-TAZ pathway in experimental NASH and is elevated in humans with NASH
by: Mary Patricia Moore, et al.
Published: (2023-05-01) -
NCOA5 Haploinsufficiency in Myeloid-Lineage Cells Sufficiently Causes Nonalcoholic Steatohepatitis and Hepatocellular CarcinomaSummary
by: Yueqi Zhang, et al.
Published: (2024-01-01)